Mind-Altering Drugs Media ArticlesExcerpts of Key Mind-Altering Drugs Media Articles in Major Media
Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.
Imagine discovering a plant that has the potential to help alleviate post-traumatic stress disorder, suicidal thoughts and paralyzing anxiety. That's what some believe ayahuasca can do, and this psychedelic drink is attracting more and more tourists to the Amazon. War vets are seeking it for PTSD. Former Marine Lance Cpl. Ryan LeCompte organizes trips to Peru for war veterans, like himself, who are seeking ayahuasca as a possible treatment for PTSD and other emotional and mental trauma suffered after multiple combat deployments. "Ayahuasca is a way to give relief to those who are suffering," says LeCompte, who says many veterans are not satisfied with the PTSD treatment they receive when they return from combat. Libby ... is one of the veterans who accompanied LeCompte to Peru to try ayahuasca for her PTSD diagnosis, which includes sexual trauma while on active duty. She says antidepressants made her more suicidal. "I would like to wish not to die all the time," she said, when asked why she was seeking ayahuasca. "I want that to go away." Those of have tried ayahuasca say that any benefits - like with other drugs or medicine - must be combined with therapy. There are efforts to study the medicinal benefits of ayahuasca, explains Rick Doblin, executive director of the Multidisciplinary Association of Psychedelic Studies. "At a time when drug policy is being reevaluated ... how ayahuasca should be handled in a regulatory context is really up in the air," Doblin said.
Note: Watch the full CNN documentary on an ayahuasca ceremony in Peru. For more along these lines, see these concise summaries of deeply revealing news articles about mind altering drugs from reliable sources.
Psychedelics, the drugs of choice for many in the 1960s counterculture movement, may be making a comeback. Scientists, doctors and scholars who have researched the health potential of drugs such as LSD, magic mushrooms and ecstasy, gathered at the Horizons conference ... to discuss innovations in the field. Psychedelics ... went out of favor with the law in the 1960s and 1970s, [which] slammed the lid on research. Those prohibitions seem to be loosening somewhat, with some governments allowing a small amount of research with psychedelic drugs, results of which show they may carry promise for treating a wide variety of ailments, from anxiety to addiction. “Some of the most significant civilizations have given an honored place to psychedelics,” scholar and writer Graham Hancock told conference attendees. Hancock said hallucinogenic mushrooms played a part in cultures such as the Mayan Civilization and were depicted in European and African cave paintings as far back as 9,000 years ago. A recently completed project at New York University found that psilocybin appears to reduce anxiety and depression in terminal cancer patients. It appeared that psilocybin led many of the study participants, who were all in various stages of life-threatening cancer, to have “mystical experiences” that gave them great insights, improved their anxiety and generally made them more positive and loving, they and their loved ones reported. To date there have been no adverse reactions to psilocybin in any study.
"People try and run away from things and to forget, but with psychedelic drugs they're forced to confront and really look at themselves," explains Dr Robin Carhart-Harris, from Imperial College London. The drugs Carhart-Harris is referring to are hallucinogens such as magic mushrooms -- specifically the active chemical inside them, psilocybin. Carhart-Harris scanned the brains of 30 healthy volunteers after they had been injected with psilocybin and found the more primitive regions of the brain associated with emotional thinking became more active and the brain's "default mode network," associated with high-level thinking, self-consciousness and introspection, was disjointed and less active. "We know that a number of mental illnesses, such as OCD and depression, are associated with excessive connectivity of the brain, and the default mode network becomes over-connected," says David Nutt, professor of neuropsychopharmacology, who leads the Imperial College team. The over-connectivity Nutt describes causes depressed people to become locked into rumination and concentrate excessively on negative thoughts about themselves. Depression is estimated to affect more than 350 million people around the world. The current pharmaceutical approach to treatment is with selective serotonin re-uptake inhibitors (SSRIs), such as Prozac. But SSRIs ... are generally prescribed for long periods of time to maintain their effect. Nutt thinks psilocybin could be a game-changer, used as part of a therapeutic package ... to treat people within just one or two doses of treatment.
Note: For more about the therapeutic uses of psychedelic drugs, see these concise summaries of deeply revealing news articles from reliable sources.
Dr Sanjay Gupta: There's a group of outlawed drugs out there that are generating new interest among a growing number of doctors. Some of these drugs include things like MDMA also known as ecstasy, also LSD. Psychiatrists have (long) been fascinated by the properties of psychedelics. The U.S. military's efforts in the 1950s ... tested LSD as a potential weapon. But the interests in these drugs didn't stay in the lab. They trickled on to the black market and were soon outlawed. The pattern repeated itself with MDMA. Therapists tried it with patients. Millions tried it on their own. And in 1985, it was banned under federal law. Over the last decade, a small band of researchers wrangled permission to try again. This time giving MDMA during therapy sessions with patients who were suffering post-traumatic stress. DR. MICHAEL MITHOEFER, TESTING MDMA AS TREATMENT FOR PTSD PATIENTS: It was revisiting the trauma that was painful. The MDMA seemed to make it possible for them to do it effectively. GUPTA: Dr. Mithoefer has treated nearly 50 patients. He's currently working with veterans. RICK DOBLIN, MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES: People are able to look at traumatic memories, the fear is reduced, and then they're able to separate out it was happening then and not now. GUPTA: So, if they're going through counselling, for example, it could make that counselling more effective, they're not as paralyzed if you will by the memories that are being brought up? DOBLIN: We're saying that MDMA itself is not the medicine, it's MDMA assisted psychotherapy.
Note: Watch this CNN news clip and decide for yourself. For more about how the CIA secretly experimented on people with LSD and other drugs, read this deeply revealing information about a project called MK ULTRA. For more about the legitimate therapeutic uses of these drugs, and how investigation into these is suppressed, see these concise summaries of deeply revealing news articles from reliable sources.
LSD, ecstasy (MDMA) and other psychedelics are powerful, mind-altering drugs that, as described by former Washington Post Magazine editor Tom Shroder, “intrinsically [challenge] the rationalist, materialist underpinnings of Western culture.” For most of a century, our society has struggled to come to grips with these “profoundly threatening drugs,” largely without success. They’ve all been made illegal. For decades, the Food and Drug Administration and the Drug Enforcement Administration have strictly banned scientific investigations into their potential benefits — which is unfortunate, since these psychoactive drugs also seem able to do incredible good, particularly in the treatment of post-traumatic stress disorder (PTSD). Every year, as many as 5 million Americans suffer from its effects. Frequent consequences include depression, drug and alcohol abuse, and a host of associated health problems. In “both humanitarian and economic terms,” the costs are staggering. And PTSD stubbornly resists treatment. Psychoactive drugs such as LSD and MDMA seem to bring powerful healing energies to bear on the underlying issues. But despite a growing mountain of evidence supporting the therapeutic benefits delivered by these drugs, government authorities have blocked scientific and therapeutic explorations of their potential. Fortunately, the government’s prohibitions may be loosening, thanks to a cadre of psychedelic advocates who have steadfastly refused to surrender to the taboos. The story of those people and their efforts to win scientific and therapeutic approval for psychedelic drugs is the central thrust of Shroder’s strangely wonderful new book, Acid Test: LSD, Ecstasy, and the Power to Heal.
Note: For more on this, see concise summaries of deeply revealing mind-altering drugs news articles from reliable major media sources.
On 5th May, 1953, the novelist Aldous Huxley dissolved four-tenths of a gram of mescaline in a glass of water, drank it, then sat back and waited for the drug to take effect. Huxley took the drug in his California home under the direct supervision of psychiatrist Humphry Osmond, to whom Huxley had volunteered himself as “a willing and eager guinea pig”. Osmond was one of a small group of psychiatrists who pioneered the use of LSD as a treatment for alcoholism and various mental disorders in the early 1950s. He coined the term psychedelic, meaning ‘mind manifesting’ and although his research into the therapeutic potential of LSD produced promising initial results, it was halted during the 1960s for social and political reasons. While at St. George’s [Hospital after WWII], Osmond and his colleague John Smythies learned about Albert Hoffman’s discovery of LSD at the Sandoz Pharmaceutical Company in Bazel, Switzerland. Osmond and Smythies started their own investigation into the properties of hallucinogens. Osmond tried LSD himself and concluded that the drug could produce profound changes in consciousness. Osmond and [Abram] Hoffer also recruited volunteers to take LSD and theorised that the drug was capable of inducing a new level of self-awareness which may have enormous therapeutic potential. In 1953, they began giving LSD to their patients, starting with some of those diagnosed with alcoholism. Their first study involved two alcoholic patients, each of whom was given a single 200-microgram dose of the drug. One of them stopped drinking immediately after the experiment. The other stopped 6 months later. Osmond and Hoffer were encouraged, and continued to administer the drug to alcoholics. Their studies seemed to show that a single, large dose of LSD could be an effective treatment for alcoholism, and reported that between 40 and 45% of their patients given the drug had not experienced a relapse after a year.
Note: For more on this, see concise summaries of deeply revealing mind-altering drugs news articles from reliable major media sources.
Researchers aren't sure why, but in the 23 U.S. states where medical marijuana has been legalized, deaths from opioid overdoses have decreased by almost 25 percent, according to a new analysis. "Most of the discussion on medical marijuana has been about its effect on individuals in terms of reducing pain or other symptoms," said lead author Dr. Marcus Bachhuber. "The unique contribution of our study is the finding that medical marijuana laws and policies may have a broader impact on public health." California, Oregon and Washington first legalized medical marijuana before 1999, with 10 more following suit between then and 2010, the time period of the analysis. Another 10 states and Washington, D.C. adopted similar laws since 2010. For the study, Bachhuber, of the Philadelphia Veterans Affairs Medical Center and the University of Pennsylvania, and his colleagues used state-level death certificate data for all 50 states between 1999 and 2010. In states with a medical marijuana law, overdose deaths from opioids like morphine, oxycodone and heroin decreased by an average of 20 percent after one year, 25 percent by two years and up to 33 percent by years five and six compared to what would have been expected, according to results in JAMA Internal Medicine. Meanwhile, opioid overdose deaths across the country increased dramatically, from 4,030 in 1999 to 16,651 in 2010, according to the Centers for Disease Control and Prevention (CDC). Three of every four of those deaths involved prescription pain medications.
Note: For more on this, see concise summaries of deeply revealing mind-altering drug news articles from reliable major media sources.
Dr Robin Carhart-Harris, a research associate in the Centre for Neuropsychopharma-cology at Imperial College, is ... the first person in the UK to have legally administered doses of lysergic acid diethylamide (LSD) to human volunteers since the Misuse of Drugs Act of 1971. Born in Durham 33 years ago and raised in Bournemouth, he ... is a careful and articulate speaker, but his enthusiasm for his work is evident. "We're at an early, but certainly promising, stage. It's really exciting," he says. The potential scientific benefits of psychedelics ... fall broadly into two categories. They look like being medicinally or therapeutically useful, and they offer an unconventional view of the workings of the human mind, such that the age-old, so-called "hard problem of consciousness" might be made a little easier. Uniquely potent in minute doses, and with what Carhart-Harris calls "a very favourable physiological safety profile" – which is to say, it is non-toxic – this newly synthesised psychedelic drug opened new doors, in more ways than one. "You could say the birth of the science of psychedelics occurred with the discovery of LSD," says Carhart-Harris. "It was only then that we started to study them systematically." Cary Grant famously used it during his therapy, as did the Alcoholics Anonymous co-founder Bill Wilson. Between the 1950s and 1965, when Sandoz withdrew the drug, there were more than 1,000 clinical papers discussing 40,000 patients. A 2012 meta-analysis of six controlled trials from the era found its clinical efficiency for the treatment of alcohol addiction to be as effective as any treatment developed since.
Note: Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
[There are many] obstacles and frustrations scientists face in trying to study the medical uses of marijuana. Dating back to 1999, the Department of Health and Human Services has indicated it does not see much potential for developing marijuana in smoked form into an approved prescription drug. In guidelines issued that year for research on medical marijuana, the agency quoted from an accompanying report that stated, “If there is any future for marijuana as a medicine, it lies in its isolated components, the cannabinoids and their synthetic derivatives.” Scientists say this position has had a chilling effect on marijuana research. Though more than one million people are thought to use the drug to treat ailments ranging from cancer to seizures to hepatitis C and chronic pain, there are few rigorous studies showing whether the drug is a fruitful treatment for those or any other conditions. A major reason is this: The federal government categorizes marijuana as a Schedule 1 drug, the most restrictive of five groups established by the Controlled Substances Act of 1970. Drugs in this category — including heroin, LSD, peyote and Ecstasy — are considered to have no accepted medical use in the United States and a high potential for abuse, and are subject to tight restrictions on scientific study. In the case of marijuana, those restrictions are even greater than for other controlled substances. Marijuana remains illegal under federal law, though nearly half the states and the District of Columbia allow its medical use and two, Colorado and Washington, have legalized its recreational use.
Note: For more on this, see concise summaries of deeply revealing government corruption news articles from reliable major media sources.
Psychedelic mushrooms can do more than make you see the world in kaleidoscope. Research suggests they may have permanent, positive effects on the human brain. In fact, a mind-altering compound found in some 200 species of mushroom is already being explored as a potential treatment for depression and anxiety. People who consume these mushrooms, after “trips” that can be a bit scary and unpleasant, report feeling more optimistic, less self-centered, and even happier for months after the fact. But why do these trips change the way people see the world? According to a study published today in Human Brain Mapping, the mushroom compounds could be unlocking brain states usually only experienced when we dream, changes in activity that could help unlock permanent shifts in perspective. The study examined brain activity in those who’d received injections of psilocybin, which gives “shrooms” their psychedelic punch. After injections, the 15 participants were found to have increased brain function in areas associated with emotion and memory. The effect was strikingly similar to a brain in dream sleep, according to Dr. Robin Carhart-Harris, a post-doctoral researcher in neuropsychopharmacology at Imperial College London and co-author of the study. Administration of the drug just before or during sleep seemed to promote higher activity levels during Rapid Eye Movement sleep, when dreams occur. An intriguing finding, Carhart-Harris says, given that people tend to describe their experience on psychedelic drugs as being like “a waking dream.”
Note: For more on this, see concise summaries of deeply revealing mind altering drugs news articles from reliable major media sources.
The explosion of dance music culture during the late '80s and early '90s conferred fame on some unlikely people, but few were quite as unlikely as Alexander Shulgin, who died on 2 June at his home in California at the age of 88. He was nearly 70 by the time he became known as the Godfather of Ecstasy, a title that made it sound like he had invented MDMA, which he hadn't: Shulgin had only introduced the drug to west coast psychotherapists in the late 70s. But, he had created more than 200 psychoactive compounds in his home laboratory, tested them all on himself and his wife and written about them in a 1991 book titled Phenethylamines I Have Known and Loved. The combination of the book, his association with ecstasy, and that drug's burgeoning popularity made him a hugely celebrated figure. Shulgin thought all drugs should be legalised, but he seemed about as far removed from the bug-eyed psychedelic proselyte of popular myth as it was possible to get. His writing was measured, calm and witty. He did not court the attention of the rave generation. If anything, he seemed faintly exasperated by the way MDMA was being used. "Go banging about with a psychedelic drug for a Saturday night turn-on, and you can get into a really bad place, psychologically," he had warned. Later he was to lament that MDMA had been "sidetracked into the Yahoo generation". None of the drugs Shulgin invented became as famous as the one he didn't. In the late '90s, there was talk that a compound called 2CB was "the new ecstasy" but it never attained the ubiquity of E. Nevertheless, Shulgin's legend was assured.
Note: To see Shulgin's fun and iconoclastic character, watch this fun four-minute video. Explore major media articles showing breakthroughs in therapy from an excellent compilation of news articles on mind altering drugs. And read the personal journey to healing of courageous CNN reporter Amber Lyon using these "medicines."
Buried in February’s $956 billion farm bill is an amendment ... that legally distinguishes industrial hemp from marijuana, after decades of conflation [of the two]. It defines hemp as an agricultural crop rather than a drug — and effectively frees American farmers to grow it for the first time in almost 60 years. For 20 years, legislators, farmers, hippies, activists, agency heads and agronomists have worked to recast hemp as a game-changer, an American cash crop that could jump-start the country's next economic revival. Colorado, Vermont and Kentucky wasted no time launching their industrial hemp research and the pilot programs provided for in the farm bill. In an obscure notice dated April 16th, the USDA alerted state and county officials that farmers in states that [approved] hemp production (15 so far) could now include hemp acreage in their crop reports. The floodgates have opened. The current American hemp market is estimated at nearly half a billion dollars, with hemp’s oil, seed and fiber used in food, carbon-negative building materials, and automobile composites that are already inside millions of cars. Hemp cultivation is ... as old as the country itself. George Washington and Thomas Jefferson grew it, hemp was once legal tender, and several drafts of the Declaration of Independence were written on hemp paper. During WWII, American farmers were paid to grow it, cultivating more than 150 million pounds of industrial hemp to support the American war effort.
Note: Hemp is derived from the cannabis sativa plant, which also produces marijuana. For news on mind altering substances, see the deeply revealing reports from reliable major media sources available here.
Psychedelic drug research is coming back. But the research still faces stigma, and funding is hard to get. Stanislav Grof was one of the leading researchers on the therapeutic applications of LSD in the 1950s and '60s. He studied the effect of hallucinogens on mental disorders, including addiction. Grof tells NPR's Arun Rath, "This was a tremendous deepening and acceleration of the psychotherapeutic process. Compared with the therapy in general, which mostly focuses on suppression of symptoms, here we had something that could actually get to the core of the problems." The Schedule 1 classification of LSD and other hallucinogenic substances in 1970 was a huge blow to research. But by the '90s, attitudes had begun to change. By the 2000s, a small but growing research community was picking up where Grof and others had left off. One area that showed promise was using hallucinogens to ease anxiety and depression in patients with cancer, like Erica Rex. "I was diagnosed with breast cancer, stage 2, in 2009," Rex says. "I went through the treatment, and then there are some drugs that have terrible side effects." She says she became obsessed with the possibility of her death, and it was crippling. Then Rex [was approved] for a study on the experimental drug psilocybin, an active compound in psychedelic mushrooms. In the end, she says, it helped her depression.
Note: Food justice champion Michael Pollan recently wrote a fascinating article prominently featured in the venerable magazine The New Yorker about the amazing power of psilocybin mushrooms to create profound healing in carefully controlled environments. It is subtitled "Research into psychedelics, shut down for decades, is now yielding exciting results." Are the healing potentials of mind altering drugs finally starting to receive honest mainstream attention?
On [March 4], The Journal of Nervous and Mental Disease is posting online results from the first controlled trial of LSD in more than 40 years. The study, conducted in the office of a Swiss psychiatrist near Bern, tested the effects of the drug as a complement to talk therapy for 12 people nearing the end of life. Most of the subjects had terminal cancer, and several died within a year after the trial — but not before having a mental adventure that appeared to have eased the existential gloom of their last days. “Their anxiety went down and stayed down,” said Dr. Peter Gasser, who conducted the therapy and followed up with his patients a year after the trial concluded. The new publication marks the latest in a series of baby steps by a loose coalition of researchers and fund-raisers who are working to bring hallucinogens back into the fold of mainstream psychiatry. Before research was effectively banned in 1966 in the United States, doctors tested LSD’s effect for a variety of conditions, including end-of-life anxiety. But in the past few years, psychiatrists in the United States and abroad — working with state regulators as well as ethics boards — have tested Ecstasy-assisted therapy for post-traumatic stress; and other trials with hallucinogens are in the works. “The effort is both political and scientific,” said Rick Doblin, executive director of the Multidisciplinary Association for Psychedelic Studies, a foundation that has financed many of the studies. “We want to break these substances out of the mold of the counterculture and bring them back to the lab.”
Note: For more on mind altering drugs, see the deeply revealing reports from reliable major media sources available here.
Over the last year, I [CNN Chief Medical Correspondent Dr. Sanjay Gupta] have been working on a new documentary called "Weed." The title "Weed" may sound cavalier, but the content is not. I traveled around the world to interview medical leaders, experts, growers and patients. I spoke candidly to them, asking tough questions. What I found was stunning. Long before I began this project, I had steadily reviewed the scientific literature on medical marijuana from the United States and thought it was fairly unimpressive. Reading these papers five years ago, it was hard to make a case for medicinal marijuana. I even wrote about this in a TIME magazine article, back in 2009, titled "Why I would Vote No on Pot." Well, I am here to apologize. I apologize because I didn't look hard enough, until now. I didn't look far enough. I didn't review papers from smaller labs in other countries doing some remarkable research, and I was too dismissive of the loud chorus of legitimate patients whose symptoms improved on cannabis. I mistakenly believed the Drug Enforcement Agency listed marijuana as a schedule 1 substance because of sound scientific proof. Surely, they must have quality reasoning as to why marijuana is in the category of the most dangerous drugs that have "no accepted medicinal use and a high potential for abuse." They didn't have the science to support that claim, and I now know that when it comes to marijuana neither of those things are true. It doesn't have a high potential for abuse, and there are very legitimate medical applications. In fact, sometimes marijuana is the only thing that works.
Note: This article was authored by CNN's Chief Medical Correspondent, Dr. Sanjay Gupta. For more on the proven benefits from many mind-altering drugs, see the deeply revealing reports from reliable major media sources available here.
'Absurd' laws dealing with magic mushrooms, ecstasy and cannabis are hindering medical research, according to a former government drugs adviser. Prof David Nutt says he has funding to research the use of the chemical psilocybin - found in fungi known as "magic mushrooms" to treat depression. But he says "insane" regulations mean he cannot get hold of the drug. The Home Office said there was "no evidence" that regulations were a barrier to research. It is not the first time Prof Nutt has been at odds with government policy. He was sacked as an adviser over views that ecstasy and LSD were less harmful than alcohol. Earlier research at Imperial College London showed that injections of psilocybin could calm a region of the brain which is overactive in depression. The UK's Medical Research Council has given the lab a Ł550,000 grant to test the idea - in 30 patients who have not responded to at least two other therapies. They have also been given ethical approval. However, there are more stringent regulations for testing the drug as a treatment than in earlier experiments. As a potential medicine it must meet Good Manufacturing Practice requirements set out by the EU. "It hasn't started yet because the big problem is getting hold of the drug," said Prof Nutt. He said finding a company to provide a clinical-grade psilocybin had "yet proved impossible" as none was prepared to "go through the regulatory hoops". He told the BBC: "We have regulations which are 50 years old, have never been reviewed and they are holding us back, they're stopping us doing the science and I think it's a disgrace actually."
Note: Watch an informative three-minute BBC news clip of an interview with Prof. Nutt. Another good five-minute BBC interview is available here. For more on this, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources. See also the website of MAPS, and excellent organization supporting scientific study of the healing powers of these drugs.
$452 million: That's the value of retail products containing imported hemp that were sold in the United States in 2011. While a cousin of marijuana, the plant can't get you high. Instead, it can be used to make clothes, horse bedding, auto parts, soap and even concrete. But thanks to it being classified like all cannabis plants as a Schedule I substance - the same as heroin - the U.S. hemp crop is precisely zero. If you want to grow hemp and avoid a jail sentence, you need a permit from the Drug Enforcement Administration.
Note: Many have suspected that hemp was outlawed along with marijuana to block competition with lumber and other industries. To see a 1938 Popular Mechanics article touting hemp as the "new billion dollar crop," click here.
More than 7 million Americans suffer from PTSD, and by most estimates, only half of them -- at best -- are ever cured. A decade ago, the widely acknowledged need for better treatments opened the door to [South Carolina psychiatrist Dr. Michael] Mithoefer and his unconventional approach. By ... February 2005, the soft-spoken, ponytailed Mithoefer had managed to convince the Drug Enforcement Administration to green-light a study of Ecstasy as an adjunct to psychotherapy. He'd gotten the 3,4-methylenedioxy-methylamphetamine (MDMA) -- the chemical name for pure Ecstasy -- from Rick Doblin, the founder of a MAPS, the Multidisciplinary Association for Psychedelic Studies. The group's stated purpose is to develop "medical, legal and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana." It wants to turn mind-altering drugs like Ecstasy into prescription medicine. To win broader acceptance for MDMA -- and for cousins like LSD and psilocybin, the mind-altering compound in so-called magic mushrooms -- "the medical route was the only route. Everything else was blocked." That meant a formal plan for drug development: study protocols, institutional review boards and the rest. Mithoefer, a University of Virginia-trained clinician who specializes in trauma and had a long-running interest in MDMA, was the perfect partner.
Note: To watch a CNN video clip on this showing remarkable success in treating PTSD, click here. For deeply revealing reports from reliable major media sources on beneficial mind-altering drugs, click here.
Hundreds of Iraq and Afghanistan veterans with post-traumatic stress have recently contacted a husband-and-wife team who work in suburban South Carolina to seek help. Many are desperate, pleading for treatment and willing to travel to get it. The soldiers have no interest in traditional talking cures or prescription drugs that have given them little relief. They are lining up to try an alternative: MDMA, better known as Ecstasy, a party drug that surfaced in the 1980s and ’90s that can induce pulses of euphoria and a radiating affection. Government regulators criminalized the drug in 1985, placing it on a list of prohibited substances that includes heroin and LSD. But in recent years, regulators have licensed a small number of labs to produce MDMA for research purposes. In a paper posted online ... by the Journal of Psychopharmacology, Michael and Ann Mithoefer, the husband-and-wife team offering the treatment — which combines psychotherapy with a dose of MDMA — write that they found 15 of 21 people who recovered from severe post-traumatic stress in the therapy in the early 2000s reported minor to virtually no symptoms today. The Mithoefers — he is a psychiatrist and she is a nurse — collaborated on the study with researchers at the Medical University of South Carolina and the nonprofit Multidisciplinary Association for Psychedelic Studies. The patients in this group included mostly rape victims, and experts familiar with the work cautioned that it was preliminary, based on small numbers, and its applicability to war trauma entirely unknown.
Note: For the paper on this remarkable study published published online in the Journal of Psychopharmacology, click here. For deeply revealing reports from reliable major media sources on beneficial mind-altering drugs, click here.
Massachusetts voters in 2˝ weeks will consider becoming the 18th state to legalize the use of marijuana for medical purposes. Individual doctors and patient advocacy groups, including the AIDS Action Committee of Massachusetts and the state chapter of the Leukemia and Lymphoma Society, have endorsed the ballot question, saying marijuana can help patients and is available now. To study marijuana, researchers must be licensed by the US Drug Enforcement Administration and get access to marijuana grown at the University of Mississippi, which contracts with the National Institute on Drug Abuse to produce the only federally sanctioned supply. That process can prove onerous, if not impossible, acting as a deterrent for those who might want to study marijuana’s benefits, some researchers said. In 2000, the University of California created the Center for Medicinal Cannabis Research, with $9 million from the state. Dr. Igor Grant, the center’s director, ... and colleagues have completed the most comprehensive research to date of the effects of marijuana in patients, including studies that were randomized and double-blind, gold standards in research. Four studies found the drug to be useful in treating pain. Three were in patients with HIV who had pain resulting from damage to their nervous system. Another study found that marijuana reduced muscle stiffness in patients with multiple sclerosis.
Note: For deeply revealing reports from reliable major media sources on mind-altering drugs, click here.
Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.